BioSeek Extends Merck Profiling Plan to 2012 | GenomeWeb

NEW YORK (GenomeWeb News) – BioSeek has extended an agreement with Merck Serono, under which it will continue to profile compounds for the drug developer for another three years, BioSeek said today.

The new agreement extends a previous compound profiling plan from 2008, which had BioSeek using its BioMap platform to evaluate small molecule compounds and proteins in different therapeutic areas. The BioMap Systems use cell-based human disease models to develop information about potential drugs that companies can use to help choose and develop candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.